Orexigen Therapeutics
AcquiredUSA, United States · Founded 2004 · $30.0M raised
- Headquarters
- USA, California
- Employees
- 51–200
- Founded
- 2004
- Business Model
- B2B
- Website
- orexigen.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series CNov 2006
- Rounds
- 2
- Acquisition Date
- Apr 2018
About
Orexigen Therapeutics was a La Jolla, California-based biopharmaceutical company focused on treatments for obesity. The company developed Contrave (naltrexone/bupropion extended-release), an FDA-approved prescription weight-loss medication. Orexigen filed for Chapter 11 bankruptcy in March 2018 and its assets were acquired by Nalpropion Pharmaceuticals.
Summary
Orexigen Therapeutics is a Biotech company based in USA, United States, founded in 2004. It has raised $30.0M in total across 2 rounds, most recently a $30.0M Series C round in Nov 2006. Investors include New Enterprise Associates, MPM BioEquities and Wasatch Ventures.
Funding History
Apr 2018
Sign up to see all 5 rounds
Secondary Market through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/orexigen-therapeutics"><img src="https://indexed.vc/api/badge/company/orexigen-therapeutics" alt="Orexigen Therapeutics on Indexed.vc" width="260" height="76" /></a>